Cystic Fibrosis Pipeline Insights 2024: FDA Aprovals, Clinical Trials, Therapies and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Cystic Fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.

The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cystic Fibrosis Pipeline Report: https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years.
• Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment
• Emerging Cystic Fibrosis therapies in the different phases of clinical trials are- SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.
• In November 2024, Spirovant Sciences initiated its SAAVe Phase I/II study, with the first patient receiving a dose of SP-101 combined with an enhancer to treat cystic fibrosis. SP-101 is an inhalable adeno-associated virus (AAV) gene therapy designed for targeted delivery to human airway epithelia. The enhancer, doxorubicin, is intended to boost the expression of the functional cystic fibrosis transmembrane conductance regulator (CFTR) transgene.
• In July 2024, Armata Pharmaceuticals finished enrolling patients for its Phase II Tailwind study, evaluating the inhaled bacteriophage therapy AP-PA02 for chronic pulmonary Pseudomonas infections. The Tailwind study is a crucial trial designed to assess the safety, tolerability, and effectiveness of AP-PA02 in patients with non-cystic fibrosis bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection.

Cystic Fibrosis Overview
Cystic Fibrosis (CF) is a genetic disorder that affects the lungs, pancreas, and other organs, leading to severe respiratory and digestive problems. It is caused by mutations in the CFTR gene, which regulates the movement of salt and water in and out of cells. This results in thick, sticky mucus buildup in the lungs, causing chronic respiratory infections and difficulty breathing. In the digestive system, CF can obstruct the release of enzymes needed for digestion, leading to malnutrition. Symptoms include coughing, wheezing, difficulty breathing, frequent lung infections, and digestive issues. While there is no cure for CF, treatments focus on managing symptoms, improving lung function, and addressing nutritional needs.

Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:
• SP-101: Spirovant Sciences
• LUNAR CF: Arcturus Therapeutics
• KB407: Krystal Biotech
• VX-522: Vertex Pharmaceuticals
• Galicaftor/Navoc aftor/ABBV-576: AbbVie
• AP-PA02: Armata Pharmaceuticals
• 4D-710: 4D Molecular Therapeutics
• ELX-02: Eloxx Pharmaceutical
• Ensifentrine: Verona Pharma
• Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceuticals
• OligoG: Algi Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense

Cystic Fibrosis Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Cystic Fibrosis Molecule Type
Cystic Fibrosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Cystic Fibrosis Pipeline Therapeutics Assessment
• Cystic Fibrosis Assessment by Product Type
• Cystic Fibrosis By Stage and Product Type
• Cystic Fibrosis Assessment by Route of Administration
• Cystic Fibrosis By Stage and Route of Administration
• Cystic Fibrosis Assessment by Molecule Type
• Cystic Fibrosis by Stage and Molecule Type

DelveInsight's Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies
https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cystic Fibrosis Pipeline Analysis:
The Cystic Fibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
• Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies
https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cystic Fibrosis Pipeline Market Drivers
• Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.

Cystic Fibrosis Pipeline Market Barriers
• However, no standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.

Scope of Cystic Fibrosis Pipeline Drug Insight
• Coverage: Global
• Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others
• Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others
• Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
• Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers

Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Cystic Fibrosis Report Introduction
2. Cystic Fibrosis Executive Summary
3. Cystic Fibrosis Overview
4. Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment
5. Cystic Fibrosis Pipeline Therapeutics
6. Cystic Fibrosis Late Stage Products (Phase II/III)
7. Cystic Fibrosis Mid Stage Products (Phase II)
8. Cystic Fibrosis Early Stage Products (Phase I)
9. Cystic Fibrosis Preclinical Stage Products
10. Cystic Fibrosis Therapeutics Assessment
11. Cystic Fibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cystic Fibrosis Key Companies
14. Cystic Fibrosis Key Products
15. Cystic Fibrosis Unmet Needs
16 . Cystic Fibrosis Market Drivers and Barriers
17. Cystic Fibrosis Future Perspectives and Conclusion
18. Cystic Fibrosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Cystic Fibrosis Market
https://www.delveinsight.com/report-store/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Cystic Fibrosis Epidemiology
https://www.delveinsight.com/report-store/cystic-fibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cystic Fibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Car-t Market: https://www.delveinsight.com/blog/car-t-cell-therapy-market-and-competitive-landscape
• Intravenous Immunoglobulin Market: https://www.delveinsight.com/report-store/intravenous-immunoglobulin-market
• Transdermal Drug Delivery Devices Market: https://www.delveinsight.com/report-store/drug-delivery-devices-market
• Coronary Angioplasty Market: https://www.delveinsight.com/report-store/coronary-angioplasty-with-or-without-stenting-market
• Artificial Pancreas Device System Market: https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
• Orthopedic Splints Device Market: https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.